Cholesterol absorption inhibition: Filling an unmet need in lipid-lowering management

European Heart Journal, Supplement

Volumn 3, Issue SUPPL.5, 2001, Pages

  Leitersdorf, E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cholesterol absorption inhibitor; Ezetimibe; Hypercholesterolaemia; Low density lipoprotein cholesterol; Statins; Target cholesterol levels

Indexed keywords

EID: 0002308639     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90108-7     Document Type: Article

References (39)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
3. Sacks FM, Pfeffer MA, Moyé LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
4. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615-22.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
6. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. J Am Med Assoc 2000; 284: 311-8.
7. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-503.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015-23.
9. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
10. Poulter NR. Medical education: communicating best practice. Atherosclerosis 1999; 143 (Suppl 1): S13-6.
11. Feely J. The therapeutic gap - compliance with medication and guidelines. Atherosclerosis 1999; 147 (Suppl 1): S31-7.
12. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991-1997. Am J Med 2000; 108: 496-9.
13. Pederson TR, Olsson AG, Faergeman O et al. Lipoprotein changes and reduction in the incidence of major CHD events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60.
14. Sacks FM, Moyé LA, Davis BR et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446-52.
15. Allison TG, Squires RW, Johnson BD, Gau GT. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. Mayo Clin Proc 1999; 74: 466-73.
16. Tikkanen MJ. Statins: within-group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996; 7: 385-8.
17. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996; 125: 990-1000.
18. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204.
19. Fruchart J-C, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipidemia and coronary heart disease. Am J Cardiol 1998; 81: 912-7.
20. Gotto A, Pownall H. Manual of Lipid Disorders, 2nd edn. Baltimore: Williams & Wilkins, 1999; chap 17: 292-5.
21. Farmer JA, Gotto AM Jr. Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Saf 1994; 11: 301-9.
22. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 441-57.
23. Kosoglou T, Meyer I, Musiol B et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin (Abstr). Atherosclerosis 2000; 151: 135.
24. Kosoglou T, Meyer I, Musiol B et al. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol (Abstr). Third International Congress on Coronary Artery Disease - from Prevention to Intervention; Lyon, France, October 2-5, 2000: 71.
25. Kosoglou T, Meyer I, Cutler DL et al. Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin (Abstr). Third International Congress on Coronary Artery Disease - from Prevention to Intervention; Lyon, France, October 2-5, 2000: 101.
26. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
27. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am 2000; 84: 23-42.
28. Barter PJ, O'Brien RC. Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 2000; 149: 199-205.
29. Rubinstein A, Weintraub M. Escape phenomenon of low-density lipoprotein cholesterol during lovastatin treatment. Am J Cardiol 1995; 76: 184-6.
30. Bradford RH, Shear CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-9.
31. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 158: 577-84.
32. Argov Z. Drug-induced myopathies. Curr Opin Neurol 2000; 13: 541-5.
33. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J.
34. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998; 19: 355-71.
35. van Heek M, Farley C, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000; 129: 1748-54.
36. van Heek M, France CF, Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63.
37. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001; 415: 79-84.
38. Bays H, Drehobl M, Rosenblatt S et al. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption, in 243 hypercholesterolemic subjects: results of a dose-response study (Abstr). Atherosclerosis 2000; 151: 133.
39. Lipka LJ, LeBeaut AP, Veltri EP et al. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): pooled analysis of two phase II studies (Abstr). J Am Coll Cardiol 2000; 35 (Suppl 2A): 257A.